Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2602 produtos para "Cromatina/Epigenética".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALKBH1-IN-1
ALKBH1-IN-1 (Compound 13h) is a selective ALKBH1 inhibitor with IC50 values of 0.026 μM in fluorescence polarization assays and 1.39 μM in enzyme activity assays. It can regulate the levels of DNA 6mA modifications and is useful for studying the functions of ALKBH1 and DNA 6mA.Fórmula:C16H11F3N4O4Peso molecular:380.07324CARM1/HDAC2-IN-1
CARM1/HDAC2-IN-1 (Compound CH-1) is a dual inhibitor targeting CARM1 and HDAC2, with IC50 values of 3.71 nM and 4.07 nM, respectively. This compound exhibits antitumor activity.Fórmula:C35H42N8O3Cor e Forma:SolidPeso molecular:622.33799Antidiabetic agent 7
Antidiabetic agent 7 (Compound 5m) functions as a potent hyperglycemia inhibitor. It effectively stimulates GLUT4 translocation in skeletal muscle cells by activating the AMPK-dependent pathway. Additionally, this compound is capable of reducing blood glucose levels and exhibits favorable pharmacokinetic properties. Antidiabetic agent 7 is suitable for research related to antihyperglycemic treatments.Fórmula:C27H21Cl2N5O3Cor e Forma:SolidPeso molecular:534.39GSK973
CAS:GSK973 is a selective oral BET inhibitor, 1600x more for BRD4 BD2 (pIC50 7.8, pKd 8.7) than BD1, effective against other BD2s.Fórmula:C23H23FN2O4Cor e Forma:SolidPeso molecular:410.445PROTAC BRD4 Degrader-13
CAS:PROTAC BRD4 Degrader-13 targets VHL and BRD4, degrading BRD4 with DC50 of 0.025/6.0 nM in PC3 cells when linked to STEAP1/CLL1 antibodies.Fórmula:C68H85F2N11O17P2S2Cor e Forma:SolidPeso molecular:1492.55INCB059872
CAS:INCB059872: potent, oral, selective LSD1 inhibitor for myeloid leukemia research.Fórmula:C23H34N2O3Cor e Forma:SolidPeso molecular:386.536Malantide
CAS:Malantide, a synthetic dodecapeptide, boosts and measures PKA activity by undergoing PKA-induced phosphorylation.Fórmula:C72H124N22O21Pureza:98%Cor e Forma:SolidPeso molecular:1633.89TYK2 activator-1
TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485MJ-26
MJ-26 is an inhibitor targeting Menin, characterized by a high binding affinity (Ki: 0.56 μM) and significant antiproliferative activity. It functions by inhibiting Menin-MLL interaction and promoting the degradation of Menin protein. MJ-26 demonstrates notable antitumor effects against acute myeloid leukemia (AML) and is applicable for AML research.MS-8709
CAS:MS-8709 is a potent and selective G9a/GLP PROTAC Degrader with a DC50(G9a) of 274 nM and a DC50(GLP) of 260 nM. It induces G9a/GLP protein degradation in a concentration-dependent and time-dependent manner via the ubiquitin-proteasome system, without affecting mRNA expression levels. MS-8709 demonstrates superior cell growth inhibition compared to the parent compound UNC0642 in prostate cancer, leukemia, and lung cancer cell models, and exhibits mouse pharmacokinetic characteristics suitable for in vivo efficacy studies.Fórmula:C64H95F2N11O7SPureza:99.98%Peso molecular:1200.57mUNO
CAS:mUNO is a tumor-homing peptide (mUNO, sequence: "CSPGAK") that specifically binds to murine CD206, targeting tumor-associated macrophages that express CD206/MRC1. Additionally, mUNO can interact with human recombinant CD206.Fórmula:C22H39N7O8SCor e Forma:SolidPeso molecular:561.652MS049 2HCl (1502816-23-0(free base))
MS049 inhibits PRMT4 (IC50=34nM) & PRMT6 (IC50=43nM), less so for PRMT1, PRMT3, PRMT8, not others.Fórmula:C15H26Cl2N2OPureza:99.9%Cor e Forma:SolidPeso molecular:321.28PKC β pseudosubstrate
CAS:Selective cell-permeable peptide inhibitor of protein kinase C (IC50 ~ 0.5 μM).Fórmula:C177H294N62O38S3Pureza:98%Cor e Forma:SolidPeso molecular:3994.84MS8535
MS8535 is a selective SPIN1 inhibitor with an IC50 value of 0.2 μM.Fórmula:C28H38N6O2Cor e Forma:SolidPeso molecular:490.30562M-1211
CAS:M 1121 is a covalent and orally active inhibitor of the menin-MLL interaction capable of achieving complete and persistent tumor regression.Fórmula:C42H57FN6O6SCor e Forma:SolidPeso molecular:793.01BAY-184
CAS:BAY-184,KAT6A/B inhibitor (IC50=71/83 nM). Suppresses ERα activity. Impedes breast cancer proliferation.Fórmula:C23H20N2O4SPureza:98.87%Cor e Forma:SolidPeso molecular:420.48pTH-Related Protein (1-40) (human, mouse, rat)
CAS:pTH-Related Protein (1-40) boosts rat calcium absorption via PTHR1 and PKCα/β. It up-regulates PTHR1, TRPV6, CaBP-D9k, NCX1, and PMCA1.Fórmula:C207H334N66O58Peso molecular:4675.27Izilendustat
CAS:Tert-butyl compound inhibits human EGLN-1; confirmed by spectrometry after 20 mins.Fórmula:C22H28ClN3O4Pureza:99.86%Cor e Forma:White SolidPeso molecular:433.93Casdatifan
CAS:Casdaitifan (AB521) is an orally active hypoxia inducible factor 2 alpha (HIF-2 alpha) inhibitor. Casdaitifan exhibits significant anti-tumor effects in the clear cell renal cell carcinoma (ccRCC) model.Fórmula:C21H17F4NO3SPeso molecular:439.42Neuropeptide DF2
CAS:Neuropeptide DF2 is an FMRFamide-related neuropeptide from crayfish.Fórmula:C44H67N15O10Pureza:98%Cor e Forma:SolidPeso molecular:966.1
